نتایج جستجو برای: mrd

تعداد نتایج: 1567  

Journal: :Blood 1998
C J Knechtli N J Goulden J P Hancock V L Grandage E L Harris R J Garland C G Jones A W Rowbottom L P Hunt A F Green E Clarke A W Lankester J M Cornish D H Pamphilon C G Steward A Oakhill

The efficacy of allografting in acute lymphoblastic leukemia (ALL) is heavily influenced by remission status at the time of transplant. Using polymerase chain reaction (PCR)-based minimal residual disease (MRD) analysis, we have investigated retrospectively the impact of submicroscopic leukemia on outcome in 64 patients receiving allogeneic bone marrow transplantation (BMT) for childhood ALL. R...

2013
Adriano Venditti Maria Ilaria Del Principe Luca Maurillo Francesco Buccisano Sergio Amadori

Transl Pediatr 2013;2(1):43-45 www.thetp.org In acute myeloid leukemia (AML), achievement of morphologic complete remission (RC) still remains the “gold standard” to make a judgment on treatment response and yet hematologists wonder about its utility in the era of minimal residual disease (MRD) detection. In fact, whatever the techniques used, a number of studies has convincingly demonstrated t...

2015
Oksana V. Arkhipova Margarita V. Meer Galina V. Mikoulinskaia Marina V. Zakharova Alexander S. Galushko Vasilii K. Akimenko Fyodor A. Kondrashov

The origin and evolution of novel biochemical functions remains one of the key questions in molecular evolution. We study recently emerged methacrylate reductase function that is thought to have emerged in the last century and reported in Geobacter sulfurreducens strain AM-1. We report the sequence and study the evolution of the operon coding for the flavin-containing methacrylate reductase (Mr...

2017
Ming Chu Kailin Yin Yujun Dong Pingzhang Wang Yun Xue Peng Zhou Yuqi Wang Yuedan Wang

Acquired drug resistance in childhood T-cell acute lymphoblastic leukemia (T-ALL) remains a significant clinical problem. In this study, a novel gene therapy target for childhood T-ALL to overcome chemoresistance was discovered: TFDP3 increased in the minimal residual disease (MRD) positive childhood T-ALL patients. Then, we established a preclinical model of resistance to induction therapy to ...

Journal: :Cancer research 2007
Shuchi Agrawal Matthias Unterberg Steffen Koschmieder Udo zur Stadt Uta Brunnberg Walter Verbeek Thomas Büchner Wolfgang E Berdel Hubert Serve Carsten Müller-Tidow

Epigenetic changes play an important role in leukemia pathogenesis. DNA methylation is among the most common alterations in leukemia. The potential role of DNA methylation as a biomarker in leukemia is unknown. In addition, the lack of molecular markers precludes minimal residual disease (MRD) estimation for most patients with hematologic malignancies. We analyzed the potential of aberrant DNA ...

Journal: :Anticancer research 2010
Satoshi Nishiwaki Koichi Miyamura Chiaki Kato Seitaro Terakura Kazuteru Ohashi Hisashi Sakamaki Shinji Nakao Hideo Harigae Yoshihisa Kodera

To evaluate the effect of post-transplant imatinib administration, 34 Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph(+)ALL) patients were retrospectively analysed, with 7 receiving post-transplant imatinib administration. Overall survival was significantly better in patients with post-transplant administration (66.7% vs. 29.6% at 3 years, p=0.03), with no significant differe...

Journal: :Blood 2014
Yu Wang De-Pei Wu Qi-Fa Liu Ya-Zhen Qin Jing-Bo Wang Lan-Ping Xu Yan-Rong Liu Hong-Hu Zhu Jia Chen Min Dai Xiao-Jun Huang

We asked whether minimal residual disease (MRD) determined by RUNX1/RUNX1T1 transcript levels could identify allogeneic hematopoietic stem cell transplantation (allo- HSCT) t(8;21) (q22;q22) acute myeloid leukemia patients who are at high risk for relapse, together with the impact of c-KIT mutations. Ninety-two consecutive adult t(8;21) patients who received allo-HSCT in complete remission were...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2015
Bruno Paiva Noemi Puig Ramón García-Sanz Jesús F San Miguel

Increasing therapeutic options and prolonged survival in multiple myeloma have raised interest in the concept of depth of response and its importance to predict patients' outcomes. Although the efficacy of current treatment approaches has greatly improved in the past decade, the definition of complete response (CR) remains unaltered and continues to use conventional serological and morphologic ...

Journal: :Blood 2013
Pau Abrisqueta Neus Villamor María José Terol Eva González-Barca Marcos González Christelle Ferrà Eugenia Abella Julio Delgado Jose A García-Marco Yolanda González Felix Carbonell Secundino Ferrer Encarna Monzó Isidro Jarque Ana Muntañola Mireia Constants Lourdes Escoda Xavier Calvo Sabela Bobillo José Bruno Montoro Emili Montserrat Francesc Bosch

The effectiveness of rituximab maintenance therapy in the treatment of chronic lymphocytic leukemia has been investigated in a phase 2 clinical trial that included an initial treatment with rituximab 500 mg/m2 on day 1 (375 mg/m2 the first cycle), fludarabine 25 mg/m2 on days 1 to 3, cyclophosphamide 200 mg/m2 on days 1 to 3, and mitoxantrone 6 mg/m2 on day 1 (R-FCM), for 6 cycles, followed by ...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2005
Amber van Stijn Nicole Feller Alice Kok Marjoleine A van der Pol Gert J Ossenkoppele Gerrit J Schuurhuis

PURPOSE Apoptosis is an important mechanism regulating survival of acute myeloid leukemia cells. The apoptosis-related protein profile at diagnosis is important for achieving complete remission thereby affecting survival variables such as disease-free survival (DFS) and overall survival (OS).To investigate the role of the apoptosis protein profile in further response to therapy and outgrowth of...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید